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Aims Iron deﬁciency (ID) and anaemia are common in patients with chronic heart failure (CHF). The presence of anaemia
is associated with increased morbidity and mortality in CHF, and ID is a major reason for the development of
anaemia. Preliminary studies using intravenous (i.v.) iron supplementation alone in patients with CHF and ID have
shown improvements in symptom status. FAIR-HF (Clinical Trials.gov NCT00520780) was designed to determine
the effect of i.v. iron repletion therapy using ferric carboxymaltose on self-reported patient global assessment
(PGA) and New York Heart Association (NYHA) in patients with CHF and ID.
Methods
and results
This is a multi-centre, randomized, double-blind, placebo-controlled study recruiting ambulatory patients with symp-
tomatic CHF with LVEF   40% (NYHA II) or  45% (NYHA III), ID [ferritin ,100 ng/mL or ferritin 100–300 ng/mL
when transferrin saturation (TSAT) , 20%], and haemoglobin 9.5–13.5 g/dL. Patients were randomized in a 2:1 ratio
to receive ferric carboxymaltose (Ferinject
w) 200 mg iron i.v. or saline i.v. weekly until iron repletion (correction
phase), then monthly until Week 24 (maintenance phase). Primary endpoints are (i) self-reported PGA at Week
24 and (ii) NYHA class at Week 24, adjusted for baseline NYHA class.
Conclusion This study will provide evidence on the efﬁcacy and safety of iron repletion with ferric carboxymaltose in CHF
patients with ID with and without anaemia.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Chronic heart failure (CHF) results in poor life expectancy,
impaired quality of life, repeated hospitalizations and is a consider-
able economic burden to society.
1 Despite advances in its treat-
ment, the prognosis of CHF remains ominous,
2 and in developed
countries, total expenditure on heart failure ranges between 1
and 2% of the total healthcare budget.
3
Patients with CHF often suffer from greatly reduced exercise
capacity, which manifests itself as excessive fatigue and breathless-
ness. These symptoms are poorly related to myocardial function
and lead to a decrease in quality of life and high morbidity.
4
Numerous mechanisms may underlie exercise limitation in CHF,
and among them inadequate oxygen supply and impaired
oxygen utilization by the exercising skeletal muscle.
5,6 Thera-
peutic options to improve functional capacity are still very
limited, but it is plausible that targeting abnormalities impeding
oxygen transportation and/or utilization may confer functional
beneﬁts.
Iron plays a crucial role in oxygen uptake and transport [as part
of the ferrous ring of haemoglobin (Hb)], oxygen storage (as a
component of myoglobin), oxygen metabolism, and energy pro-
duction (as a component of oxidative enzymes and respiratory
chain proteins) and is involved in erythropoiesis.
7,8 Therefore,
iron deﬁciency (ID), with or without concomitant anaemia, may
be associated with reduced functional capacity and is often
accompanied by subjective complaints of poor physical condition
with objective indices of exercise intolerance such as diminished
oxygen consumption, and attenuated submaximal exercise per-
formance (Figure 1).
9,10 The correction of ID in anaemic and non-
anaemic patients without heart failure has been shown to improve
cognitive, symptomatic, and exercise performance.
11,12 If clinical
symptomatology of CHF resembles that of ID, one can simply
imply impaired iron homeostasis as one of the mechanisms
underlying exercise intolerance in CHF. Interestingly, ID as a
problem in the CHF syndrome has only recently gained clinical
interest, which coincided with the recognition of anaemia as a
frequent co-morbidity in CHF.
Estimates of the prevalence of anaemia in patients with CHF
vary signiﬁcantly, from 4 to 61%, and are related to clinical charac-
teristics of the studied population. Anaemia is more common in
the elderly, those with advanced CHF, concomitant renal dysfunc-
tion, diabetes mellitus, greater oedema, lower blood pressure,
higher use of diuretics, and elevated levels of neurohormones
and proinﬂammatory cytokines.
13 Recent data from a cohort of
6159 consecutive outpatients with stable CHF revealed a preva-
lence of anaemia at baseline of 17%, with new-onset anaemia
developing at 6-month follow-up in 16% of patients without
prior anaemia.
14 Data from clinical trials have shown that during
the course of 1 year, new anaemia developed in 10–17% of
CHF patients.
15,16 In CHF patients, even mild anaemia is associated
with worsening of symptoms, increased New York Heart Associ-
ation (NYHA) class and impaired functional capacity, quality of
life, and survival.
17 The cost of hospitalization for anaemic CHF
patients is higher than for non-anaemic CHF patients.
18
Anaemia of chronic disease is characterized by a marked dysre-
gulation of iron metabolism, in particular by a reduced level of iron
available for erythropoiesis. Chronic heart failure is an inﬂamma-
tory state with elevated levels of proinﬂammatory cytokines,
which in turn block the intestinal absorption of iron and the
release of iron, derived from phagocytised senescent red blood
cells from the reticuloendothelial system, causing a ‘reticuloen-
dothelial block’.
19 Hepcidin, a small peptide produced by the
liver in response to proinﬂammatory cytokines, has been shown
to play a key role in the control of these processes.
20 In this clinical
situation, decreased iron absorption together with an accumulation
within the reticuloendothelial stores leads to limited iron avail-
ability for erythropoiesis and subsequently iron-deﬁcient
anaemia.
19 Since the main feature of this type of anaemia is an
impaired mobilization of iron from cells, it may occur despite ade-
quate iron stores in the body and, it is named ‘functional ID’ in con-
trast to absolute ID, when body iron stores are signiﬁcantly
depleted.
Ferric carboxymaltose, a new intravenous (i.v.) iron preparation,
is designed to provide a high iron bioavailability without the disad-
vantageous characteristics associated with iron dextran, ferric glu-
conate, and iron sucrose therapy. Ferric carboxymaltose is
dextran-free and thus does not react with dextran antibodies
(therefore not requiring a test dose) and has a pH between 5.0
and 7.0. The pharmacokinetic properties of ferric carboxymaltose
in humans lie between those of iron dextran and iron sucrose, i.e.
the calculated terminal half-life is 16 h (in comparison to 3–4
days for iron dextran and 6 h for iron sucrose). The mechanism
and the extent of utilization of iron are similar to that of iron
sucrose.
21
FAIR-HF (Ferinject
w Assessment in patients with IRon deﬁciency
and chronic Heart Failure) was designed to test whether correc-
tion of ID using i.v. iron (ferric carboxymaltose) confers beneﬁts
in symptomatic CHF patients with and without anaemia.
Figure 1 Effect of iron deﬁciency on erythropoiesis and
oxygen metabolism. Adapted from Haas and Brownlie
9 and
Dallman.
10
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Study design
FAIR-HF is a multi-centre, double-blind, randomized, placebo-controlled
parallel group study which is being conducted in 75 study sites mainly in
Europe and Argentina. The study design is summarized in Figure 2.
The study is conducted in accordance with the principles stated in
the Declaration of Helsinki (1996), International Conference on Har-
monisation Good Clinical Practice, and local and national regulations.
Written informed consent has been provided by all patients prior to
any study-related procedures.
Eligibility
The main FAIR-HF study inclusion and exclusion criteria are listed in
Table 1. Brieﬂy, ambulatory CHF patients in NYHA class II or III,
with a LVEF   40% (NYHA II) or  45% (NYHA III), with presence
of ID (deﬁned as ferritin ,100 ng/mL or ferritin 100–300 ng/mL
when TSAT ,20%) and Hb between 9.5 and 13.5 g/dL (all at screen-
ing) were included. Patients with uncontrolled hypertension, other sig-
niﬁcant heart disease, inﬂammation, or signiﬁcantly impaired liver or
renal function were excluded. Pregnant women were excluded, and
women with childbearing potential must not become pregnant
during the study.
Figure 2 Study ﬂow-chart. Abbreviations: CHF, chronic heart failure; ID, iron deﬁciency; i.v., intravenous; LVEF, left ventricular ejection frac-
tion; NYHA, New York Heart Association; PGA, patient global assessment; TSAT, transferrin saturation.
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Randomization was achieved using a central Interactive Voice
Response System to allocate patients to treatment groups and avoid
any selection bias. Patients were stratiﬁed according to regions and
randomized in a 2:1 ratio (ferric carboxymaltose:placebo).
Study treatment
Active treatment
Ferric carboxymaltose solution (Ferinjectw, Vifor International) for
parenteral application, 50 mg iron/mL iron. Medication is given as an
i.v. bolus of 200 mg iron in 4 mL (can be 100 mg iron i.v. in 2 mL for
last injection in correction phase).
Placebo
Normal saline (0.9% w/v NaCl) is administered in analogy to the active
treatment.
For all patients, the total iron dose required for iron repletion is cal-
culated at baseline, based on the mean of two Hb values obtained on
site during the screening period. Calculations are done using the
Ganzoni formula.
22
Iron deﬁcit [mg] ¼ body weight (b.w.) [kg]
†   (15 – actual Hb)
[g/dL]   2.4
†† þ 500 [mg]
†††
In both treatment groups, study drug is administered in doses of
4 mL once weekly up to calculated iron repletion. The calculated
dose is rounded to the next 100 mg iron. After the correction
phase, study drug is given monthly in doses of 4 mL from Week 8
(or week 12, depending on the number of infusions required during
the correction phase) until Week 24 (maintenance phase).
Adjustment algorithm
Incase ofelevatedlevelsofferritin .800 ng/mL orferritin .500 ng/mL
when TSAT .50% or Hb .16 g/dL at any stage, iron treatment is
discontinued and placebo is given instead. In this case, ferritin,
TSAT, and Hb are re-checked every 2 weeks (correction phase) or
every 4 weeks (maintenance phase). Once ferritin has dropped to
,400 ng/mL and TSAT to ,45% and Hb to ,16 g/dL, treatment
with iron can be restarted. In case severe anaemia develops (i.e.
Hb   9 g/dL), the patient is to discontinue treatment but remain in
the study, and further management of anaemia is at the investigator’s
discretion.
Blinding
The ferric carboxymaltose solution is dark brown in appearance and is
therefore easily distinguishable from the placebo (0.9% saline). Hence,
unblinded study personnel (at least one physician) not involved in any
study assessments are responsible for preparing and administering the
study treatment injections in black syringes and using a curtain (or
similar) to maintain patient blinding. Unblinded personnel make sure
the patient is not able to observe the preparation of study treatment
injections. To ensure the blinded investigator remains blinded, post-
baseline iron values are sent by the central laboratory only to the
...............................................................................................................................................................................
Table 1 Summary of key inclusion and exclusion criteria at screening
Key inclusion criteria Key exclusion criteria
NYHA II–III functional class due to stable symptomatic CHF and all of the
following
Known active infection, C-reactive protein.20 mg/L, clinically signiﬁcant
bleeding, active malignancy
Two weeks without cardiac hospitalization ALT or AST .3  upper limit of normal
Patients in NYHA II: acute care admission or emergency room visit for
worsening heart failure within 24 months prior to start of treatment
Anaemia due to reasons other than iron deﬁciency (e.g.
haemoglobinopathy)
On optimal pharmacological treatment which includes a diuretic, a
beta-blocker, and/or an ACE-inhibitor or ARB as determined by the
investigator, unless contraindicated or not tolerated
Immunosuppressive therapy or renal dialysis
No dose changesof heart failure drugs during the last 2 weeks (exception:
diuretics)
History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in
previous 12 weeks and/or such therapy planned within the next 6
months
No introduction of a new heart failure drug class during the last 4 weeks Unstable angina pectoris, clinically signiﬁcant uncorrected valvular disease
or left ventricular outﬂow obstruction, obstructive cardiomyopathy
LVEF  40% for patients in NYHA II and LVEF   45% in NYHA III Acute myocardial infarction or acute coronary syndrome, transient
ischaemic attack or stroke within the last 3 months
Hb: 9.5–13.5 g/dL Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac,
cerebrovascular, aortic; diagnostic catheters are allowed) or major
surgery, including thoracic and cardiac surgery, within the last 3 months
Evidence of absolute or functional iron deﬁciency: screening ferritin
,100 ng/mL or 100–300 ng/mL when TSAT , 20%
Patient must be able to perform the 6 minute walk test according to
investigator judgement
ACE, angiotensin-converting enzyme; ALT, alanine transaminase; ARB, angiotensin II receptor blocker; AST, aspartate transaminase; CHF, chronic heart failure; Hb, haemoglobin;
i.v., intravenous; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; TSAT, transferrin saturation.
†In patients with a body mass index .25, a normalized weight will be used to calcu-
late the iron deﬁcit. Normalized weight [kg] ¼ 25   height [m]   height [m].
††Factor 2.4 ¼ 0.0034 (iron content Hb ¼ 0.34%)   0.07 (blood volume ¼ 7% of
body weight)   10000 (conversion g/dL to mg/L).
†††Depot iron.
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ence of elevated iron levels or severe anaemia. In case of elevated iron
parameters or severe anaemia, the unblinded physician amends the
study treatment as described above.
Assessments
Planned clinical assessments for efﬁcacy are completed for all patients
who start investigational drug. In addition to screening and baseline
visits, assessments are completed at Weeks 4, 12, and 24. A follow-up
visit is completed at Week 26 (or within 2 weeks after last treatment).
Primary efﬁcacy assessments for NYHA functional class and self-
reported patient global assessment (PGA) are performed at weeks
4, 12 and 24.
Study endpoints
The primary endpoints are self-reported PGA score at Week 24 and
NYHA class at Week 24, adjusted for baseline NYHA class.
Key secondary endpoints are:
† PGA score at Weeks 4 and 12
† NYHA class at Weeks 4 and 12, adjusted for baseline NYHA class
† Six minute walk test (6MWT) distance at Weeks 4, 12, and 24,
adjusted for baseline distance
† Kansas City Cardiomyopathy Questionnaire scores (overall
summary score and all sub-scores) at Weeks 4, 12, and 24, adjusted
for baseline
† European Quality of Life-5 Dimensions (EQ-5D) questionnaire
score (visual assessment score and all sub-scores) at Weeks 4, 12,
and 24, adjusted for baseline
† Health resource utilization at each assessment time point
† Days alive and out of hospital
† Hospitalization (total, cardiovascular, due to worsening of CHF)
† Mortality (total, cardiovascular, due to worsening of CHF)
† Change in estimated glomerular ﬁltration rate (e-GFR)
† Standard safety assessments (adverse events, vital signs, physical
examinations, 12-lead electrocardiograms, clinical laboratory panels).
Statistical considerations
Sample size
Sample size calculations are based on the PGA score and NYHA class
24 weeks after start of iron repletion. A two-group t-test with a 0.025
two-sided signiﬁcance level has 90% power to detect a difference in
PGA score means of 0.900, assuming that the common standard devi-
ation is 2.407, when the sample sizes in the two groups are 134 and
268, respectively (a total sample size of 402). A two-group t-test
with a 0.025 two-sided signiﬁcance level has 90% power to detect a
difference in NYHA class means of 0.500, assuming that the
common standard deviation is 1.337, when the sample sizes in the
two groups are 134 and 268, respectively (a total sample size of
402). With an estimated rate of 10% of patients without a Week 24
assessment, we aimed to recruit 442 patients.
Statistical analysis
Two analysis populations will be distinguished—full analysis set (FAS)
and per-protocol (PP) analysis population. The analysis will be per-
formed according to the intention-to-treat principle, by assigned
study treatment and ignoring changes to study treatment during
follow-up. The FAS will comprise all patients for whom study treat-
ment administration was started. The PP analysis population will com-
prise all patients for whom study treatment administration was started
and for whom no major baseline protocol violations were present.
Analyses will be available for the FAS and PP analysis populations.
The primary efﬁcacy analysis will be based on the FAS. For the
primary efﬁcacy analysis, the 24 week changes from baseline for the
two co-primary outcomes (i.e. NYHA class, adjusted for the baseline
value, and the PGA score) will be compared using standard, two-sided
signiﬁcance tests. Alpha adjustment will be made using the method of
Benjamini and Hochberg.
23 The P-values for the two tests (P-value of
the treatment covariate in the ordered polytomous regression for the
PGA and NYHA values, respectively) will be ordered in size (P1 P2).
P2 will be compared with a signiﬁcance level of 5%. If P2   5%, both
alternative hypotheses will be proven. If P2.5% and P1   2.5%, the
corresponding alternative hypothesis of the smaller P-value (H1) will
be proven. Time-to-event data will be analysed by Kaplan–Meier
plots and appropriate event rates using person-time ‘at risk’ denomi-
nators will be given. Secondary and subgroup analyses for efﬁcacy
and safety analyses will also be performed. Descriptive statistics will
include means, standard deviations, medians, and ranges for continuous
variables (including changes), and frequency distributions for discrete
variables. The Statistical Analysis Plan will clearly describe the analytic
methods that will be used to analyse the data.
Study management
A Data Safety Monitoring Board (DSMB) independently monitors the
safety of the study participants and suggests amendments to the pro-
tocol if deemed necessary for reasons of patient safety or feasibility
of study procedures. The DSMB also includes an independent statis-
tician. The independent statistician performs analyses on safety data
in support of the DSMB during the study. To minimize potential
bias, DSMB members do not have direct contact with the study site
personnel or with study patients.
Study status
The study protocol and amendments have been approved by all
relevant regulatory authorities and participating centre’s Ethics
Committees. The ﬁrst patient was randomized on 13 July 2007, and
the last patient was randomized on 30 December 2008.
Discussion
Studies on the epidemiology and pathophysiology of ID in CHF are
rare, and there is no gold standard to diagnose ID in CHF. Ezeko-
witz et al.
24 have shown that, according to hospital discharge
records, 17% of CHF patients had anaemia and, of the latter,
21% also show a diagnosis of ID. Case records as source of epide-
miological information, however, require physicians to remember
this issue and to perform appropriate diagnostic tests. Hence
this may be an underestimate of the true frequency of ID in
CHF. Opasich et al.
25 studied 148 patients with CHF and low Hb
level. They found that the majority of the patients (57%) presented
with anaemia of chronic disease, and in this group nearly all (92%)
demonstrated defective iron supply for erythropoiesis and/or
blunted endogenous erythropoietin production. Nanas et al.
26
used bone marrow biopsies to investigate the aetiology of
anaemia in advanced CHF in 37 patients admitted to hospital
(NYHA IV, mean LVEF 22%). The authors found that 73% of
them suffered from ID anaemia, as conﬁrmed by the depletion
of iron stores in the bone marrow aspirates. Interestingly, iron-
deﬁcient patients had fairly normal levels of iron metabolism
blood biomarkers (i.e. ferritin, transferrin saturation (TSAT),
iron). Grzeslo et al.
27 reported a high prevalence of ID among
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Table 2 Summary of previous studies using intravenous iron in patients with chronic heart failure
Authors n Design Inclusion (Hb, ferritin) Regimen and total iron dose per
protocol
Follow-up
time
Key results
Bolger et al.
31 16 Open, no control Hb   12 g/dL and Ferritin   400 ng/
mL
Iron sucrose, maximum 1000 mg iron i.v. over
a 17-day period (200 mg iron on Days 1, 3,
5, plus Days 15 and 17, if ferritin ,400 ng/
mL on day 12)
3 months "Hb
"QoL
"Exercise capacity (6MWD)
Toblli et al.
32 40 Double-blind,
randomized,
placebo-controlled
Hb , 12.5 g/dL for men; ,11.5 g/
dL for women
Iron sucrose, 200 mg iron i.v. weekly for
5 weeks (total 1000 mg iron)
6 months "Hb
Ferritin ,100 ng/mL and/or
TSAT   20%
"QoL
"Exercise capacity (6MWD)
"LVEF
#Hospitalizations
#NYHA
"Renal function
#NT-proBNP level
Okonko et al.
33 35 Single blind, randomized,
controlled
Hb , 12.5 g/dL (anaemic group) Iron sucrose, 200 mg iron i.v. weekly until
ferritin  500 ng/mL (correction phase),
then 200 mg iron every 4 weeks
(maintenance phase) to Week 16
4 months #HF symptoms (PGA)
12.5–14.5 g/dl (non-anaemic group) Required iron dose calculated using Ganzoni
formula: body weight (kg)   2.4   [15—
patient’s Hb (g/dl)] þ 500 mg (for stores)
"Exercise tolerance (peak VO2)
Ferritin ,100 ng/mL or 100–
300 ng/mL with TSAT , 20%
#NYHA
#Fatigue score
Usmanov et al.
34 32 Open, no control Hb , 11 g/dL Iron sucrose, 100 mg iron i.v. three times
weekly for 3 weeks, then once weekly for
23 weeks (total 3200 mg iron)
6 months "Hb
Ferritin not speciﬁed #NYHA (in NYHA class III patients)
Echocardiographic indices: #PWT, #ST (in
NYHA class III), #LVESD, #LVESV, #LVEDD
(in NYHA class III), #LVEDV, #LVMI, "LVEF
(in NYHA class III)
6MWT, 6 min walking distance; Hb, haemoglobin; HF, heart failure; i.v., intravenous; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; LVMI, left ventricular mass index; NT-proBNP, NT-pro-brain natriuretic peptide; NYHA, New York Heart Association; PGA, Patient’s Global
Assessment; PWT, posterior wall thickness; QoL, quality of life; ST, septal thickness; TSAT, transferrin saturation; VO2, oxygen consumption.
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9an unselected cohort of CHF patients. The authors studied
165 consecutive, symptomatic, stable CHF patients under
optimal pharmacological therapy and used the following laboratory
criteria of ID: ferritin ,100 ng/mL or if ferritin 100–300 ng/mL,
TSAT , 20%. Thirty-eight percent of patients fulﬁlled laboratory
criteria for ID, which was related to disease severity and status
of low-grade inﬂammation. They also reported that ID was associ-
ated with poor outcome independently of standard prognostica-
tors and Hb level.
27
In disease areas other than HF, ID has been linked to the pres-
ence of anaemia, and several studies have investigated the effects of
a combination of treatment based on erythropoiesis stimulating
agents with oral or i.v. iron. Many of these studies demonstrated
meaningful beneﬁts of such therapy, not only to correct anaemia
or ID, but also to improve clinical indices.
28–30 A study investi-
gating the effects of darbepoietin alpha given together with i.v.
iron to CHF patients is not available.
Patients with CHF suffer from excessive fatigue, breathlessness,
and a reduced exercise capacity that all lead to decreased quality of
life. Iron deﬁciency, either with or without anaemia, can worsen all
these symptoms. If correction of ID in anaemic and non-anaemic
patients with CHF using i.v. iron could be linked with clinical
beneﬁts, this would ultimately prove the pathophysiological impor-
tance of ID in CHF. To date, four studies have been reported
(Table 2). Bolger et al.
31 in a short study, showed that iron given
intravenously as iron sucrose over 5–17 days improved Hb,
reduced symptoms and improved exercise capacity over a
3-month follow-up period in anaemic patients with CHF. Toblli
et al.
32 further demonstrated that 5 weeks of i.v. iron sucrose treat-
ment in anaemic CHF patients (baseline NYHA class III or IV and
LVEF , 35%) improved quality of life, 6MWT distance, and LVEF
and reduced the number of hospitalizations compared with con-
trols. Plasma levels of N-terminal pro-brain natriuretic peptide
and C-reactive protein also decreased.
Another study by Okonko et al.
33 conﬁrmed beneﬁts of i.v. iron
loading with iron sucrose in CHF patients. The authors random-
ized 35 (18 anaemic and 17 non-anaemic) patients with sympto-
matic CHF and abnormal iron metabolism to 16 weeks of i.v.
iron sucrose or no treatment. Iron therapy was well tolerated
and improved exercise capacity and symptoms. Beneﬁts were
more evident in anaemic patients. Increments in peak oxygen con-
sumption related only to increments in TSAT, a putative marker of
circulating iron status, but not to changes in Hb levels. Finally, in
patients with severe CHF, anaemia and chronic kidney insufﬁ-
ciency, Usmanov et al.
34 demonstrated that correction of
anaemia using i.v. iron sucrose over a prolonged period
(26 weeks) resulted in beneﬁcial effects on electrocardiographic
indices of cardiac remodelling, including improvement in cardiac
hypertrophy, cardiac dilation, and ejection fraction. An improve-
ment in NYHA status was observed in 47% of NYHA class III
patients, but no improvement was seen in NYHA class IV patients.
In patients with chronic CHF and ID, treatment with oral iron
has not been assessed in a double blind study. Oral iron has gastro-
intestinal side effects and limited absorption, which may limit its
use in chronic illness.
Furthermore, a pilot, randomized, double-blind, controlled
phase II study
35 was previously conducted to compare the efﬁcacy
and safety of ferric carboxymaltose and iron sucrose vs. standard
therapy in 72 patients with CHF (NYHA II–IV class), renal
failure (GFR , 60 mL/min) and ID (Hb at screening: 10–14.5 g/dL;
ferritin ,100 ng/mL or 100–300 ng/mL with TSAT , 20%, or
hypochromic red cells .10%). Iron was dosed weekly (i.v. injec-
tions of 200 mg iron or 100 mg iron for the last dose, if necessary)
until the calculated iron dose was reached, then one injection
(200 mg iron) every 4 weeks until Week 12.
35 From this
12-week pilot study, an improvement in PGA score was observed
in 80% of patients in the ferric carboxymaltose group and in 74% of
patients in the iron sucrose group, and an improvement in NYHA
class by one step, from baseline to last observation, was observed
in 23 and 33% of patients, respectively. Also, a lesser proportion of
patients in the placebo group showed an improvement in PGA
score or improvement in NYHA class (47 and 13%, respectively).
However, none of the between group differences in PGA or
change in NYHA between last observation and baseline was stat-
istically signiﬁcant (Data on ﬁle, Vifor Pharma Ltd). The dosing
schedule used in this study in patients with CHF did not raise
any clinically relevant safety concerns; the safety proﬁle of ferric
carboxymaltose was similar to that of placebo.
35 Although these
data are encouraging, they require conﬁrmation in a larger
placebo controlled study.
FAIR-HF is an international, multi-centre, randomized, placebo
controlled study and it will provide important efﬁcacy and safety
information on the impact of i.v. iron supplementation in CHF.
FAIR-HF will enable us to make statements about the health econ-
omic impact that i.v. iron therapy may have in CHF patients.
Study Committees
Executive Committee Members: S.D.A. (Chair), P.P. (Co-Chair),
J.C.C., G.F., R.W., K.D., H.D. (deceased), T.F.L., P.A.P.-W.
(deceased).
DSMB Members: Jacobus Lubsen, SOCAR Research SA, 18,
Chemin Chantemerle, Nyon 2, Switzerland. Rudolf P. Wu ¨thrich,
Klinik fu ¨r Nephrologie, Universita ¨tsspital, Ra ¨mistrasse 100,
Zu ¨rich, Switzerland.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
Acknowledgements
We acknowledge the editorial assistance in preparing this manu-
script of Alison Dev, PhD, PAREXEL International Ltd, based on
input and guidance provided by the authors.
Conﬂict of interest: S.D.A., P.P., J.C.C., G.F., R.W., K.D., H.D.,
and T.L. are members of the FAIR-HF steering committee. S.D.A.
and R.W. are consultant and has received honoraria for speaking
from Vifor Pharma Ltd and Amgen Inc. S.D.A. has received honor-
aria for speaking from Roche Pharma and Teva. G.F., T.L., and H.D.
have received honoraria for speaking from Vifor Pharma Ltd. P.P. is
a consultant and has received honoraria for speaking from Vifor
S.D. Anker et al. 1090Pharma Ltd. C.M. and B.E.R. are employees of Vifor Pharma Ltd,
Switzerland and hold stock in Galenica Ltd. SP has no conﬂicts
to declare.
Funding
The study is sponsored by Vifor Pharma Ltd. Funding to pay the Open
Access publication charges for this article was provided by Vifor
Pharma Ltd.
References
1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
Poole-Wilson PA, Stro ¨mberg A, van Veldhuisen DJ, Atar D, Hoes AW,
Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008: the Task
Force for the diagnosis and treatment of acute and chronic heart failure 2008
of the European Society of Cardiology. Developed in collaboration with the
Heart Failure Association of the ESC (HFA) and endorsed by the European
Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933–989.
2. Roger VL, Weston SA, Redﬁeld MM, Hellermann-Homan JP, Killian J, Yawn BP,
Jacobsen SJ. Trends in heart failure incidence and survival in a community-based
population. J Am Med Assoc 2004;292:344–350.
3. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J
Heart Fail 2001;3:283–291.
4. Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD,
Fletcher BJ, Fleg JL, Myers JN, Sullivan MJ, American Heart Association Commit-
tee on exercise, rehabilitation, prevention. Exercise and heart failure: a statement
from the American Heart Association Committee on exercise, rehabilitation, and
prevention. Circulation 2003;107:1210–1225.
5. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in chronic heart failure:
central role of the periphery. J Am Coll Cardiol 1996;28:1092–1102.
6. Harrington D, Anker SD, Chua TP, Webb-Peploe K, Ponikowski P,
Poole-Wilson PA, Coats AJ. Skeletal muscle function and its relation to exercise
tolerance in chronic heart failure. J Am Coll Cardiol 1997;30:1758–1764.
7. Fairbanks V, Beutler E. Iron deﬁciency. In Beutler E (ed.), Williams Hematology. 6th
ed. New York: McGraw-Hill; 2001. p295–304 and p.447–440.
8. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new
millennium. Trends Cell Biol 2007;17:93–100.
9. Haas JD, Brownlie T IV. Iron deﬁciency and reduced work capacity: a critical
review of the research to determine a causal relationship. J Nutr 2001;131:
676S–688S.
10. Dallman PR. Iron deﬁciency: does it matter? J Intern Med 1989;226:367–372.
11. Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial
bioenergetics, oxygen supply, and work capacity during dietary iron deﬁciency
and repletion. Am J Physiol 1982;242:E418–E427.
12. Satija P, Ondo WG. Restless legs syndrome: pathophysiology, diagnosis and treat-
ment. CNS Drugs 2008;22:497–518.
13. Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers
in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine bio-
chemical markers. Int J Cardiol 2009;132:303–311.
14. Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-
term prognosis of new-onset, transient, and persistent anemia in ambulatory
patients with chronic heart failure. J Am Coll Cardiol 2008;51:569–576.
15. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT,
Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN. Anemia and change in
hemoglobin over time related to mortality and morbidity in patients with
chronic heart failure: results from Val-HeFT. Circulation 2005;112:1121–1127.
16. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A,
Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA. The impact
of new onset anaemia on morbidity and mortality in chronic heart failure:
results from COMET. Eur Heart J 2006;27:1440–1446.
17. Szachniewicz J, Petruk-Kowalczyk J, Majda J, Kaczmarek A, Reczuch K, Kalra PR,
Piepoli MF, Anker SD, Banasiak W, Ponikowski P. Anaemia is an independent
predictor of poor outcome in patients with chronic heart failure. Int J Cardiol
2003;90:303–308.
18. Nordyke RJ, Kim JJ, Goldberg GA, Vendiola R, Batra D, McCamish M,
Thomasson JW. Impact of anemia on hospitalization time, charges, and mortality
in patients with heart failure. Value Health 2004;7:464–471.
19. Weiss G, Goodnough LT. Anemia of chronic disease. N Eng J Med 2005;352:
1011–1023.
20. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to
differential diagnosis. Haematologica 2008;93:90–97.
21. Crichton RR, Danielson BG, Geisser P. Iron Therapy with Special Emphasis on Intra-
venous Administration. 4th ed. London, Boston: International Medical Publishers;
2008.
22. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities.
Schweiz Med Wochenschr 1970;100:301–303.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Statist Soc 1995;B57:289–300.
24. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure
and is associated with poor outcomes: insights from a cohort of 12,065 patients
with new-onset heart failure. Circulation 2003;107:223–225.
25. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R,
Fucili A, Moratti R, Tramarin R, Tavazzi L. Blunted erythropoietin production and
defective iron supply for erythropoiesis as major causes of anaemia in patients
with chronic heart failure. Eur Heart J 2005;26:2232–2237.
26. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG,
Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE,
Anastasiou-Nana MI. Etiology of anemia in patients with advanced heart failure.
J Am Coll Cardiol 2006;48:2485–2489.
27. Grzeslo A, Jankowska EA, Witkowski T, Okonko DO, Majda J, Anker SD,
Poole-Wilson PA, Banasiak W, Ponikowski P. Iron deﬁciency: a frequent and
morbid condition in patients with chronic heart failure. Eur Heart J 2007;28
(Abstract Suppl):773.
28. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D,
Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction
of mild anemia in severe, resistant congestive heart failure using subcutaneous
erythropoietin and intravenous iron: a randomized controlled study. J Am Coll
Cardiol 2001;37:1775–1780.
29. Mancini DM, Katz SD, Lang CC, Lamanca J, Hudaihed A, Androne AS. Effect of
erythropoietin on exercise capacity in patients with moderate to severe
chronic heart failure. Circulation 2003;107:294–299.
30. Comin-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres AG, Serrat R, Bruguera J.
A pilot evaluation of the long-term effect of combined therapy with intravenous
iron sucrose and erythropoietin in elderly patients with advanced chronic heart
failure and cardio-renal anemia syndrome. J Cardiac Fail doi:10.1016/j.card-
fail.2009.05.010. Published online ahead of print 29 June 2009.
31. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R,
Chapman CM. Intravenous iron alone for the treatment of anemia in patients
with chronic heart failure. J Am Coll Cardiol 2006;48:1225–1227.
32. Toblli JE, Lombran ˜a A, Duarte P, Di Gennaro F. Intravenous iron reduces
NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure
and renal insufﬁciency. J Am Coll Cardiol 2007;50:1657–1665.
33. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M,
Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA,
Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance
in anemic and nonanemic patients with symptomatic chronic heart failure and iron
deﬁciency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll
Cardiol 2008;51:103–112.
34. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without ery-
thropoietin for the treatment of iron deﬁciency anemia in patients with moderate
to severe congestive heart failure and chronic kidney insufﬁciency. J Nephrol 2008;
21:236–242.
35. Arutyunov GP, Bylova NA, Ivleva AY, Kobalava ZD. The safety of intravenous
(i.v.) ferric carboxymaltose versus i.v. iron sucrose in patients with chronic
heart failure (CHF) and chronic kidney disease (CKD) with iron deﬁciency
(ID). Eur J Heart Fail 2009;8(Suppl. 2):ii71.
Intravenous iron supplementation in patients with and without anaemia 1091